Findings

What do systematic reviews say?

9 questions · 10 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 60%GRADE not reported 0 · 0%Very low 2 · 20%Low 1 · 10%Moderate 0 · 0%High 1 · 10%

Leukotriene receptor antagonist vs placebo

Clinical improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Withdrawals due to adverse events · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.1 [0.21, 21.39]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs usual care

Exacerbations · autumn asthma exacerbations in children

The review found no eligible studies for this question.

2 findings from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.5 [0.17, 1.46]
2 studies · 1326 participants
Low

Leukotriene receptor antagonist vs usual care

Adverse events · autumn asthma exacerbations in children

Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).

1 finding from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.91 [0.63, 1.32]
2 studies · 1326 participants
High